1. Home
  2. GUT vs TRDA Comparison

GUT vs TRDA Comparison

Compare GUT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Utility Trust (The)

GUT

Gabelli Utility Trust (The)

HOLD

Current Price

$6.19

Market Cap

555.5M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.05

Market Cap

500.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GUT
TRDA
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
555.5M
500.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GUT
TRDA
Price
$6.19
$6.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
185.7K
577.1K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
10.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.32
$4.93
52 Week High
$6.33
$16.45

Technical Indicators

Market Signals
Indicator
GUT
TRDA
Relative Strength Index (RSI) 52.25 29.05
Support Level $6.11 $5.58
Resistance Level $6.31 $6.90
Average True Range (ATR) 0.07 0.97
MACD -0.01 -0.55
Stochastic Oscillator 37.21 3.88

Price Performance

Historical Comparison
GUT
TRDA

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: